Piramal board approves scheme for pharma business demerger

The pharmaceuticals business will get vertically demerged from Piramal Enterprises and consolidated under Piramal Pharma, the company said in a regulatory filing.

Following the demerger, Piramal Pharma will become one of the large pharma firms listed on NSE and BSE, it added.

"In consideration of the demerger, Piramal Pharma Ltd (PPL) shall issue 4 fully paid-up equity shares of PPL of ₹10 each to the shareholders of PEL for every 1 fully paid-up equity share in PEL having a face value of ₹2 each held by them, in accordance with the Share Entitlement Ratio," Piramal Enterprises Ltd (PEL) said.

Two operating subsidiaries wholly-owned by Piramal Pharma will also be amalgamated with Piramal Pharma Ltd to further simplify the pharma corporate structure, it added.

"In line with our stated strategy, the board has approved the demerger and simplification of our corporate structure, to create two independent listed entities in financial services and pharmaceuticals, with a leadership position across the business segments they operate in," he added.

It will firmly empower both entities to be future-ready and enable them to independently pursue their growth strategies with sharper focus and identity, Piramal said.

"Piramal Pharma will be a large India-listed pharma company with proven capabilities in contract development and manufacturing, global distribution of complex hospital generics, and a large geographic footprint in the consumer products market in India," he added.

Piramal Pharma's contract development and manufacturing (CDMO) business is one of the top three in India and the 13th largest globally. PPL's complex hospital generics and India consumer healthcare businesses are well positioned with differentiated products and business models, Piramal said.

Regarding the financial services, "the amalgamation of PHL Fininvest Pvt Ltd with PEL will create a listed non-banking financial services (NBFC) entity. The merged housing finance company, post DHFL acquisition, will remain a 100% subsidiary of PEL," the filing said.

Also Read:Piramal Pharma completes acquisition of Hemmo Pharma for Rs 775 crore